VEROPHARM OAO : OJSC “VEROPHARM” announces operational performance indicators of the first half of 2013

PRESS-RELEASE

FOR IMMEDIATE DISTRIBUTION

According to the results of the first half of 2013 total sales of the top five best selling Rx drugs amounted to RUR 741.79 million, which corresponds to 41.4% of sales in the Rx drugs segment and 31.0%[1] of the Company's total sales.
According to the results of the first half of 2013 the top five best selling Rx drugs are:
o Geptor (Ademetionine; ATC[2] «Digestive tract and metabolism»); sales increased by
45.1% as compared to the same period of the previous year; 16.3% of sales in the Rx
drugs segment;

o Tautax (Docetaxel; ATC «Antineoplastic and immunomodulating agents»); sales in the segment made 7.1%;

o Irunine (Itraconazole; ATC «Antimicrobials for systematic use»); sales in the segment made 7.1%;

o Cerepro (Choline Alfoscerate; ATC «Medications for the treatment of the nervous system deseases»); sales in the segment made 5.6%;

o Parclitaxel-LENS (Parclitaxel; ATC «Antineoplastic and immunomodulating agents»);

sales in the segment made 5.3%;

OTC drugs segment is characterized by the high degree of consolidation. It means that the top five best selling medicines make 98.4% of sales.

o Xilen (Xylometazoline; ATC «Medications for the treatment of respiratory system»);

sales in the OTC drugs segment made 40.6%;

o Slabilen (Sodium picosulfate; ATC «Alimentary tract and metabolism»); sales in the

OTC drugs segment made 36.7%;
o Motilak (Domperidone; ATC «Alimentary tract and metabolism»); sales in the OTC
drugs segment made 17.5%;

o Vitasharm and Vitatress (ATC «Vitamins»); sales in the OTC drugs segment made 2.7%;

o Ginkgo biloba (Ginkgo biloba; ATC «Medications for the treatment of urogenital organs»); sales in the OTC drugs segment made 0.9%.

107023, Moscow, Russia, Ochakovskoe shosse, 10-2-1, tel.: (+7495) 792 5330

According to the results of the first half of 2013 the top five best selling prescription medications are:
o Vero-Dexamethasone (Dexamethasone; ATC «Hormonal drugs for systematic use»);
sales in the traditional drugs segment made 38.3%;
o Vero-Ciprofloxacin (Ciprofloxacin; ATC «Antimicrobials for systematic use»); sales in the segment made 17.3%;
o Vero-Loperamide (Loperamide; ATC «Alimentary tract and metabolism»); sales in the segment made 15.2%;
o Pyridoxine (ATC «Alimentary tract and metabolism»); sales in the segment made
14.8%;
o Vero-Flukonazole (Fluconazole; ATC «Antimicrobials for systematic use»); sales in the segment made 8.0%;

According to the results of the first half of 2013 the top five best selling non-pharamaceutical products are:

o Conventional antimicrobial adhesive bandages; 44.2% of sales in the segment;

o Conventional reel adhesive bandages; 26.7% of sales in the segment;

o Therapeutic patches - corn plasters; 12.3% of sales in the segment;

o Therapeutic patches - pepper plasters; 9.0% of sales in the segment;

o Condoms; 7.2% of sales in the segment.

During the first half of 2013 Veropharm launched production and sales of the following new drugs:

o Anfibra (Enoxaparin sodium; ATC «Medications affecting hematogenesis and blood»);

o Salbutamol (Salbutamol; ATC «Medications for the treatment of respiratory system»).
In the first half of 2013 Veropharm has initiated the sales of condoms under its own brand name:

o «Sensex» (Condoms; ATC «Medical items»).

During the first half of 2013 Veropharm received registration for the following 2 drugs:
o ACP (Escitolapram, ATC «Medications for the treatment of the nervous system deseases»);

o Gistamel (Imatinib; ATC « Antineoplastic and immunomodulating agents»)

Additionally, 21 more drugs are currently at different stages of the registration process.

107023, Moscow, Russia, Ochakovskoe shosse, 10-2-1, tel.: (+7495) 792 5330

[1] % - percent of finished goods sales

[2] ATC - anatomico-therapeutico-chemical group

For further information please call Veropharm OJSC:

Maksutova Nadiya,

Chief Financial Officer

maksutova.nadiya@veropharm.rutel. (+7495) 792 53 30

Or visit web-site of the Company www.veropharm.ru

VEROPHARM OJSC is one of the largest Russian pharmaceutical manufacturers.

Shares of the Company are traded at MICEX (ticker: VFRM). Market capitalization of the Company as of August

30, 2013 totaled RUR 8,351 billion (according to RTS).

The charter capital of the Company makes 10 million ordinary shares.

VEROPHARM OJSC is the market leader in Russia for production of plasters and oncological medicines. The Company's production facilities comprise 3 pharmaceutical plants in Belgorod, Voronezh and Pokrov. The Company's product portfolio includes more than 300 items. VEROPHARM OJSC employs about 2,000 people.

In the annual research conducted by the portal SuperJob.ru among Russian companies OJSC "VEROPHARM" is recognized as one of the most attractive employers in the labor market and is awarded the status of "Attractive employer-2012".

According to IMS Health, following the results of the first half of 2013 Veropharm occupies the 6th position in the

rating "Russian pharmaceutical manufacturers in production volume terms".

According to IMS Health, following the results of the first half of 2013, as compared to the same period of the previous year, Veropharm takes the following positions among Russian and foreign manufacturers in the rating "Oncology drugs manufacturers":

o 8th place in monetary terms

o 1st place in physical terms (occupies the leading position).

THIS DOCUMENT IS NOT AN ADVERTISEMENT OF SECURITIES IN THE RUSSIAN FEDERATION, AND IS NOT AN OFFER TO SELL, OR AN INVITATION TO MAKE OFFERS TO PURCHASE, ANY SECURITIES IN THE RUSSIAN FEDERATION.

NOT FOR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.

This document may include statements that are "forward-looking statements", including future operating results of the Company. These forward-looking statements involve risk and uncertainty regarding implementation of future activities. As a result, actual future results may differ materially from the plans, goals and expectations set out in these forward-looking statements. The Company undertakes no obligation to change these statements to reflect actual results.

This document does not contain a public offer to purchase securities in the US. The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be

offered or sold in the United States or to US persons.

This communication is being distributed only to and is directed only at (a) persons outside the United Kingdom, (b) persons who have professional experience in matters relating to investments, i.e., investment professionals within the meaning of

Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), and (c) high net

worth companies, unincorporated associations and other bodies to whom it may otherwise lawfully be communicated in accordance with Article 49 of the Order (all such persons together being referred to as "relevant persons"). The securities are available only to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities wil l be available only to or will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.

107023, Moscow, Russia, Ochakovskoe shosse, 10-2-1, tel.: (+7495) 792 5330

distributed by